Cancer Archives

News and Trends 7 Dec 2016

Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies

Nordic Nanovector has bagged €55M to push its pipeline forward through the clinic. Investors seem to be attracted by its ARC and ADC programs, using some of the hottest antibody technologies to treat cancer. Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat non-Hodgkin lymphoma (NHL) and recently entered the trending antibody-drug conjugate (ADC) field to fight against leukemia. These […]

December 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Dec 2016

Sanofi Jumps into the Biosimilars Market aiming for Asia

Sanofi is joining the biosimilars trend to challenge Roche’s best-selling biological with a partnership that aims to take over the Chinese cancer market. Sanofi is going after the €6.8B ($7.3B) that Roche’s Rituxan/MabThera (rituximab), the second top-selling biological, made last year in revenues. The French pharma has signed a deal worth up to €219M ($236M) […]

December 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Dec 2016

How is European Immuno-Oncology fighting Blood Cancer?

From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year’s edition of the American Society of Hematology (ASH) annual meeting features immuno-oncology therapies developed by the best European biotechs, with Novartis taking the lead in the CAR-T field. The 58th ASH annual meeting is wrapping up today, after the best companies […]

December 6, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Dec 2016

Another Pharma sloughs off Small Molecules to focus on Biologics

BI has taken an axe to its small molecule discovery program in order to focus on immuno-oncology in the latest farewell to old-school chemical drugs. Over 90% of the drugs on the market today are small molecules, but the bell has been tolling for these therapies for some time now as biopharma is increasingly focused […]

December 5, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 5 Dec 2016

Video: Chatting with Immunocore about the Potential of Immuno-oncology

At Refresh in Paris, I had the opportunity to ask Eva-Lotta Allan,CBO of one of Europe’s hottest companies, Immunocore, some pointed questions. Immunocore is famous as one of the biggest biotech successes in Europe: the company raised the largest round ever on the continent (€300M!), built a solid technological platform and recruited top talents to manage […]

December 5, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 2 Dec 2016

Better than ADCs? AstraZeneca bids for Bicyclic Peptides

AstraZeneca has signed a deal with Bicycle Therapeutics that could exceed €1B. The foundation is bicyclic peptides, which combine the best of antibodies and small molecules. Could Bicycle Drug Conjugates (BDCs) outperform ADCs? Bicycle Therapeutics is a company in Cambridge founded by one of the top biotech leaders in the UK’s golden triangle. Its unique technology […]

December 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Dec 2016

Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer

PharmaMar announced positive preclinical results for an ADC candidate, showing that the traditional chemistry-based pharma companies are shifting towards the new generation of biologicals. PharmaMar is an oncology pharma in Madrid mining a vast source for drug discovery: marine organisms. The company is now pivoting to a more innovative technology with the announcement of positive […]

December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Dec 2016

7 European Institutions in the Largest Cancer Bioinformatics Collaboration

Europe’s best companies using bioinformatics to tackle cancer will take part in a huge collaboration aimed at developing personalized cancer vaccines. Three biotech companies and four research institutions from Europe are taking part in the Tumor Neoantigen Selection Alliance (TESLA). This is one of the biggest oncology collaborations ever, consisting of 30 organizations and led by […]

December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Nov 2016

FDA and EMA review the First Therapy for a Deadly Skin Cancer

Merck and Pfizer have been granted priority review by the FDA for the first treatment dealing with one of the most aggressive forms of skin cancer. The FDA has accepted Merck and Pfizer‘s market application for avelumab in metastatic Merkel cell carcinoma (MCC) with priority review. Just a month ago, the EMA also accepted their application. If […]

November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Nov 2016

UPDATE: GSK is staging a comeback with a new Shingles Vaccine

GSK is banishing concerns about its health with a BLA submission for Shingrix, which has outperformed Merck’s standard and could bring GSK close to €1Bn. London-based GSK has just submitted a Biologics License Application to the FDA for its shingles vaccine candidate, Shingrix. Though it is still experimental, the vaccine is proving itself superior to the […]

November 30, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 30 Nov 2016

Drugging the Undruggable: New Acquisition to Boost GPCR Drugs

Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its pipeline and keep competitors in this profitable field at bay. Heptares Therapeutics develops therapies directed to G protein-coupled receptors (GPCRs), a large family of hot but elusive targets for biopharma. The British company, owned by the Japanese Sosei, just announced it […]

November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 29 Nov 2016

The ABCs of ADCs: A Review of Antibody Drug Conjugates

Antibody therapies have a little sister who is catching up in funding – and hype? In light of now five deaths from Juno’s CAR-T therapy, antibody drug conjugates are attracting a lot of interest in a resurgence after their debut 10 years ago. To feel out the field, we talked to two CEOs competing directly […]

November 29, 2016 - 8 minutesmins - By Evelyn Warner

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies

Sanofi Jumps into the Biosimilars Market aiming for Asia

How is European Immuno-Oncology fighting Blood Cancer?

Another Pharma sloughs off Small Molecules to focus on Biologics

Video: Chatting with Immunocore about the Potential of Immuno-oncology

Better than ADCs? AstraZeneca bids for Bicyclic Peptides

Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer

7 European Institutions in the Largest Cancer Bioinformatics Collaboration

FDA and EMA review the First Therapy for a Deadly Skin Cancer

UPDATE: GSK is staging a comeback with a new Shingles Vaccine

Drugging the Undruggable: New Acquisition to Boost GPCR Drugs

The ABCs of ADCs: A Review of Antibody Drug Conjugates

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!